Protein biomarkers for subtyping breast cancer and implications for future research: a 2024 update.

IF 3.8 3区生物学 Q1 BIOCHEMICAL RESEARCH METHODS

Expert Review of Proteomics Pub Date : 2024-09-01 Epub Date: 2024-11-03 DOI:10.1080/14789450.2024.2423625

Claudius Mueller, Justin B Davis, Virginia Espina

{"title":"Protein biomarkers for subtyping breast cancer and implications for future research: a 2024 update.","authors":"Claudius Mueller, Justin B Davis, Virginia Espina","doi":"10.1080/14789450.2024.2423625","DOIUrl":null,"url":null,"abstract":"Introduction: Breast cancer subtyping is used clinically for diagnosis, prognosis, and treatment decisions. Subtypes are categorized by cell of origin, histomorphology, gene expression signatures, hormone receptor status, and/or protein levels. Categorizing breast cancer based on gene expression signatures aids in assessing a patient's recurrence risk. Protein biomarkers, on the other hand, provide functional data for selecting therapies for primary and recurrent tumors. We provide an update on protein biomarkers in breast cancer subtypes and their application in prognosis and therapy selection.Areas covered: Protein pathways in breast cancer subtypes are reviewed in the context of current protein-targeted treatment options. PubMed, Science Direct, Scopus, and Cochrane Library were searched for relevant studies between 2017 and 17 August 2024.Expert opinion: Post-translationally modified proteins and their unmodified counterparts have become clinically useful biomarkers for defining breast cancer subtypes from a therapy perspective. Tissue heterogeneity influences treatment outcomes and disease recurrence. Spatial profiling has revealed complex cellular subpopulations within the breast tumor microenvironment. Deciphering the functional relationships between and within tumor clonal cell populations will further aid in defining breast cancer subtypes and create new treatment paradigms for recurrent, drug resistant, and metastatic disease.","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":" ","pages":"401-416"},"PeriodicalIF":3.8000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Proteomics","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1080/14789450.2024.2423625","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Breast cancer subtyping is used clinically for diagnosis, prognosis, and treatment decisions. Subtypes are categorized by cell of origin, histomorphology, gene expression signatures, hormone receptor status, and/or protein levels. Categorizing breast cancer based on gene expression signatures aids in assessing a patient's recurrence risk. Protein biomarkers, on the other hand, provide functional data for selecting therapies for primary and recurrent tumors. We provide an update on protein biomarkers in breast cancer subtypes and their application in prognosis and therapy selection.

Areas covered: Protein pathways in breast cancer subtypes are reviewed in the context of current protein-targeted treatment options. PubMed, Science Direct, Scopus, and Cochrane Library were searched for relevant studies between 2017 and 17 August 2024.

Expert opinion: Post-translationally modified proteins and their unmodified counterparts have become clinically useful biomarkers for defining breast cancer subtypes from a therapy perspective. Tissue heterogeneity influences treatment outcomes and disease recurrence. Spatial profiling has revealed complex cellular subpopulations within the breast tumor microenvironment. Deciphering the functional relationships between and within tumor clonal cell populations will further aid in defining breast cancer subtypes and create new treatment paradigms for recurrent, drug resistant, and metastatic disease.

查看原文本刊更多论文

用于乳腺癌亚型鉴定的蛋白质生物标志物及其对未来研究的影响：2024 年更新。

导言：乳腺癌亚型临床用于诊断、预后和治疗决策。亚型是根据起源细胞、组织形态学、基因表达特征、激素受体状态和/或蛋白质水平进行分类的。根据基因表达特征对乳腺癌进行分类有助于评估患者的复发风险。另一方面，蛋白质生物标记物为选择原发性和复发性肿瘤的疗法提供了功能数据。我们将介绍乳腺癌亚型中蛋白质生物标记物的最新情况，以及它们在预后判断和疗法选择中的应用：在当前蛋白质靶向治疗方案的背景下，对乳腺癌亚型中的蛋白质通路进行了综述。在PubMed、Science Direct、Scopus和Cochrane图书馆检索了2017年至2024年8月17日期间的相关研究：翻译后修饰的蛋白质及其未修饰的对应物已成为从治疗角度定义乳腺癌亚型的临床有用生物标志物。组织异质性会影响治疗效果和疾病复发。空间分析揭示了乳腺肿瘤微环境中复杂的细胞亚群。破译肿瘤克隆细胞群之间和内部的功能关系将进一步帮助确定乳腺癌亚型，并为复发、耐药和转移性疾病创造新的治疗范例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Proteomics 生物-生化研究方法

CiteScore

7.60

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Proteomics (ISSN 1478-9450) seeks to collect together technologies, methods and discoveries from the field of proteomics to advance scientific understanding of the many varied roles protein expression plays in human health and disease. The journal coverage includes, but is not limited to, overviews of specific technological advances in the development of protein arrays, interaction maps, data archives and biological assays, performance of new technologies and prospects for future drug discovery. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion - a personal view on the most effective or promising strategies and a clear perspective of future prospects within a realistic timescale Article highlights - an executive summary cutting to the author''s most critical points.